Powered by

Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone

Nov 20, 2018 - Thomson Reuters ONE

Idorsia Pharmaceuticals Ltd. / Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

- Vamorolone in clinical development for Duchenne muscular dystrophy (DMD) by ReveraGen BioPharma Inc. - pivotal VISION-DMD Phase 2b study ongoing

- Vamorolone has the potential to become standard of...